Ernexa Therapeutics Inc (ERNA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is significantly weak, with no revenue and substantial losses in the latest quarter. Technical indicators suggest a bearish trend, and there are no significant positive catalysts or trading signals to justify immediate investment. It is advisable to monitor the stock for further developments, particularly after the upcoming investor webcast.

Technical Analysis

The MACD is positive and expanding, indicating some bullish momentum. However, RSI is neutral at 29.239, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with support at 0.281 and resistance at 0.381. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

aimed at treating ovarian cancer.

Neutral/Negative Catalysts

Additionally, there are no significant trading trends from hedge funds or insiders, and no recent congress trading data.

Financial Performance

In Q3 2025, Ernexa reported a 100% YoY revenue drop to $0, a 95.34% YoY decline in net income to -$1,240,000, and a 99.80% YoY drop in EPS to -0.15. Gross margin also fell to 0, down 100% YoY. Overall, the financial performance is extremely poor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast ERNA stock price to rise

Buy

Hold

Sell

Current: 0.285

Low

Averages

High